MedPath

Clinical trial of Methyl-prednisolone pulse conbined therapy for Refractory Kawasaki Disease: Trial in Single Institutio

Not Applicable
Conditions
Kawasaki diease
Registration Number
JPRN-UMIN000005021
Lead Sponsor
Kitasato University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Exclusion criteria included a previous diagnosis, the presence of coronary artery aneurysms, and other contraindications to steroid therapy.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
First outcome defined a antipyretic potency at 36 hours after completion of the initial treatment.
Secondary Outcome Measures
NameTimeMethod
Second outcome defined a envaluation of coronary artery at 36 hours and 1 month after the end of thrapy.
© Copyright 2025. All Rights Reserved by MedPath